Harriet Link-Amster
Nestlé
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Harriet Link-Amster.
Journal of Pediatric Gastroenterology and Nutrition | 1992
Oscar Brunser; Julio Espinoza; Guillermo Figueroa; Magdalena Araya; Eugenic Spencer; Helmut Hilpert; Harriet Link-Amster; Harald Brüssow
Two groups of 124 and 108 children, respectively, living in urban Santiago, Chile in low socioeconomic conditions were prospectively followed for 6 months for their incidence of diarrhea. Each cohort was divided into two subgroups receiving either a commercial milk formula or the same formula containing 1% (wt/wt) bovine milk immunoglobulin concentrate from cows hyperimmunized with human rotaviruses and the major enteropathogenic Escherichia coli (EPEC) serogroups. Neither group differed with respect to incidence of diarrhea (98 episodes in 117 treated children versus 95 episodes in 115 control children), duration and clinical symptoms of diarrhea, and weight gain. Furthermore, neither group differed with respect to isolation of rotavirus (14 and 13 isolates in treatment and control groups, respectively) and isolation of enteropathogenic E. coli (14 and 15 isolates in treatment and control groups, respectively). The treatment but not the control formula contained neutralizing antibody against all human rotavirus serotypes. Titers were comparable to human breast milk samples. All isolated EPEC serogroups were included in the vaccine used for the immunization of the cows. The treatment, but not the control formula, protected mice against a lethal challenge with an EPEC strain. In conclusion, feeding an antibody-supplemented formula had no positive effect on diarrheal diseases under the conditions of a fairly well-controlled small-scale field trial.
Monatsschrift Kinderheilkunde | 1998
Ferdinand Haschke; W. Wang; Guozai Ping; Wandee Varavithya; Amornrath Podhipak; Florence Rochat; Harriet Link-Amster; Andrea Pfeifer; Erika Diallo-Ginstl; Philippe Steenhout
SummaryClinical trials to prove the safety and efficacy of follow-up formulas and growing-up milks fortified with Bifidobacterium strain Bb12 (107–108/g formula powder) are summarized in this report. The strain Bb12 was selected because of its excellent survival during intestinal transit and adhesion to enterocytes. Double-blind, randomized, controlled feeding studies with Bb12 in the U.S., China, and Thailand demonstrated normal growth of healthy children between 4 and 36 months of age and catch-up growth in malnourished children. ”Colonization” with Bb12, which indicates survival during intestinal transit, was confirmed when Bb12 was given with milk-based formulas, but was not satisfactory with soy-based formulas. Feeding the milk-based formula with Bb12 resulted in protection from rotavirus infection, fewer periods with hard bowel movements and a lower incidence of diaper rash. Therefore, using follow-up formulas and growing-up milks with Bifidobacterium strain Bb12 is safe and can prevent diseases frequently seen in both industrialized and developing countries.ZusammenfassungKlinische Studien sind notwendig, um die Sicherheit und Wirksamkeit von Folge- und Kleinkindermilch zu beweisen, der Bifidobacterien vom Stamm Bb12 (107–108/Gramm Milchpulver) zugegeben wurden. Dieser Bakterienstamm wurde gewählt, weil er die Darmpassage überleben kann und eine Adhäsionsfähigkeit an Enterozyten besitzt. Randomisierte, kontrollierte Doppelblindstudien in den USA, China und Thailand zeigten, daß gesunde Kinder im Alter zwischen 4 und 36 Monaten bei Ernährung mit einer mit Bb12 versetzten Folgemilch normal wuchsen. Kinder mit Malnutrition zeigten ein Aufholwachstum. Bb12 konnte bei den Kindern im Stuhl nachgewiesen werden, die eine mit Bb12 versetzte Folge- oder Kleinkindermilch auf Kuhmilchbasis erhielten. Bei Ernährung mit Soyamilch, die mit Bb12 versetzt war, war das gastrointestinale Überleben der Bakterien jedoch nicht ausreichend. Die Ernährung mit Folge- oder Kleinkindermilch auf Kuhmilchbasis und Bb12 Zusatz führte zu einer niedrigeren Inzidenz von Rotavirus Infektionen, Obstipation und Windeldermatitis. Es konnte daher in den klinischen Studien einerseits die Sicherheit von Folge- und Kleinkindermilch mit Bb12 gezeigt werden, andererseits tragen diese Nahrungen zur Verhütung einiger Erkrankungen bei, die sowohl in Industrie- als auch in Entwicklungsländern häufig beobachtet werden.
Archive | 2001
Ferdinand Haschke; Anne-Lise Carrie; Zdenek Kratky; Harriet Link-Amster; Florence Rochat
Archive | 2004
Ferdinand Haschke; Anne-Lise Carrie; Zdenek Kratky; Harriet Link-Amster; Florence Rochat
Fems Microbiology Letters | 1988
Jean-Richard Neeser; Arlette Chambaz; Kim Yen Hoang; Harriet Link-Amster
Archive | 2005
Rochat Florence; Carrie Anne-Lise; Kratky Zdenek; Ferdinand Haschke; Harriet Link-Amster
Archive | 2001
Anne-Lise Carrie; Ferdinand Haschke; Zdenek Kratky; Harriet Link-Amster; Florence Rochat
Archive | 2001
Ferdinand Haschke; Anne-Lise Carrie; Zdenek Kratky; Harriet Link-Amster; Florence Rochat
Archive | 2001
Ferdinand Haschke; Anne-Lise Carrie; Zdenek Kratky; Harriet Link-Amster; Florence Rochat
Archive | 2001
Ferdinand Haschke; Anne-Lise Carrie; Zdenek Kratky; Harriet Link-Amster; Florence Rochat